Latest Conference Articles

In an interview with HCPLive, Gallo described his AAAAI presentation on the function of the skin microbiome, as well as the microbiome’s connection to atopic dermatitis.

New data from the 2023 AAAAI conference showed that the mice with atopic dermatitis used in the study had different responses to ILC2 activity depending on their age.

Bryn Pharma CEO shares promising data on a novel intranasal epinephrine spray called Utuly during the AAAAI 2023 Annual Meeting.

In another segment of his interview at the 2023 AAAAI conference, Shamji spoke about comparisons between subcutaneous and sublingual immunotherapies.

A study from the AAAAI 2023 Annual Meeting reveals racial and ethnic disparities in the management of severe asthma and highlights the need for interventions to improve care escalation for Black and Hispanic/Latino patients.

In an interview at the 2023 AAAAI conference, Shamji spoke about the key points made in his presentation titled ‘Biomarkers for the Response to Allergen Immunotherapy.’

Chovatiya discussed his Winter Clinical Miami presentation, common concerns over black box warnings for JAK inhibitors, and unmet needs of alopecia areata patients.

In his latest HCPLive interview, regarding a presentation at Winter Clinical Miami, Chovatiya spoke about recent JAK inhibitor developments, alopecia areata, baricitinib, and more.

In her latest HCPLive interview, Ablon discusses her Winter Clinical Miami dermatology conference presentation ‘Evaluating the Aesthetic Patient’ and its biggest takeaways.

In an HCPLive interview on her Winter Clinical Miami presentation, Graber describes several new developments in the dermatology space regarding acne and rosacea treatments.

In another segment of his interview, Mark Lebwohl, MD, discussed the various ways to address different psoriasis patients depending on their backgrounds with obesity, cancer, and psoriatic arthritis.

In his recent interview, Mark Lebwohl, MD, spoke about his Winter Clinical Miami presentation titled ‘Psoriasis: Which Drug for Which Patient?’ and some of its highlights.

Anisha Dua, MD, MPH, emphasized the looming workforce shortage, the challenges of attracting medical students to this field, and how practices changed during the COVID-19 pandemic.

The connection between different ADHD subtypes and mood disorders has not been fully explored.

Singh presented during the recent APSARD conference. onthe topic of ADHD and bipolar disorder.

The FDA has approved several biologics in recent years for the treatment of patients with inflammatory bowel disease.

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.

Crosbie presented results from a small pilot study testing a video game platform for patients with executive function deficits during the annual APSARD meeting.

There is not much data available on the interaction between Paxlovid and tacrolimus.

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

A discussion with Henry Lim, MD, during an interview segment in which he described photoprotection measures for various skin phenotypes and his outlook on future research.

The 12-24 session counseling program also resulted in improvements in sleep quality, fatigue level, and stress levels for patients with inflammatory bowel disease.

The majority of patients who achieved persistence at the 12 month mark were also corticosteroid free.

The product is a combination of herbal compounds curcumin and QingDai called CurQD.

Microscopic inflammation can be an important indicator of disease activity in patients with ulcerative colitis.

An interview segment on HCPLive with James Del Rosso, DO, in which he explores key highlights from his presentation at the 2023 Winter Clinical conference.